Avacta Group PLC (LSE:AVCT) has announced positive Phase 1b clinical results for faridoxorubicin (AVA6000) in patients with salivary gland cancer. Across the Phase 1a and 1b studies, the treatment achieved a 90% disease control rate, with data indicating meaningful tumour reduction and extended progression-free survival.
The findings support the potential of Avacta’s pre|CISION® platform to deliver targeted cancer therapies by activating potent drugs directly within the tumour environment. The company believes the results highlight an opportunity to address unmet medical needs in salivary gland cancer and potentially other solid tumours, with additional trial data expected in the first half of 2026.
Despite the encouraging clinical progress and supportive technical indicators, Avacta’s broader outlook remains constrained by financial pressures. Ongoing losses, valuation concerns and reliance on external funding continue to weigh on the investment case, even as corporate developments point to longer-term potential.
More about Avacta Group plc
Avacta Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology therapies using its proprietary pre|CISION® platform. The technology is designed to selectively activate highly potent treatments within tumour tissue, limiting damage to healthy cells. Avacta’s pipeline includes pre|CISION® peptide drug conjugates and Affimer®-based therapies, offering an alternative approach to traditional antibody-drug conjugates.
Leave a Reply